and Ra 223 dichloride. While these agents have been shown to prolong overall survival, the benefits conferred are modest, and mCRPC remains a leading cause of cancer death, killing over 300,000 men worldwide annually (2) .
BACKGROUND
Prostate-specific membrane antigen (PSMA) is a 750 amino acid type II transmembrane glycoprotein encoded by the folate hydrolase 1 gene located on the short arm of chromosome 11 (3) . The name PSMA is a misnomer, as the protein is expressed on both benign and malignant prostate epithelium, but also on a variety of extra-prostatic tissues, including proximal renal tubules,(4) the jejunal brush border,(5) salivary glands,(5) and in the neovasculature of several solid tumors (6) . Structurally, the transmembrane protein consists of a 19-amino-acid intracellular domain, a 24-amino-acid transmembrane domain and a large, 707-amino-acid extracellular domain (7) .
by NYU Med Ctr Lib -Periodicals Dept on October 6, 2017. For personal use only. jnm.snmjournals.org Downloaded from Histologically, PSMA is detectable at modest levels in the epithelium of benign prostate tissue, but demonstrates 100x-1000x fold expression levels on the epithelium of prostate adenocarcinomas (4, 8) . It is expressed in a majority of tumors, and a positive correlation has been observed between higher PSMA expression and various measures of tumor aggressiveness, including Gleason grade (8) , tumor stage(9), biochemical recurrence(10), and castration resistance (11) . The cytoplasmic domain of PSMA contains an internalization motif which results in bound PSMA being internalized via clathrin coated pits (12) . This process provides the possibility that PSMA-targeting agents could be internalized and concentrated within tumor cells. PSMA is thus an attractive target for diagnostic and therapeutic targeting for a number of reasons, including (1) high expression on prostate cancer cells (2) limited expression on benign prostate tissue (3) limited expression on non-prostate tissue (4) an extracellular domain which can be targeted by antibodies (5) a well-characterized binding-site which can be targeted by small-molecule ligands, and (6) an internalization motif that results in bound agents being internalized and concentrated within malignant cells.
TARGETING AGENTS

Antibodies
The first steps in targeting PSMA took place in the late 1980s and involved the generation of the 7E11-C35 antibody, which is specific for an epitope at the intracellular domain of PSMA (13) . This antibody was then labeled with 111 indium, allowing for use with SPECT imaging. This agent, known as capromab pendetide (Prostascint) was FDA approved in 1996 for the detection of soft-tissue metastases. When evaluated for use in initial staging, two large multicenter trials demonstrated sensitivities ranging from 52-62%, with specificities of 72-96%, using pelvic lymphadenectomy as the truth standard, outperforming both computed tomography (CT) and magnetic resonance imaging (MRI) (14) . When used for the detection of suspected recurrent or residual cancer following treatment of the primary tumor, Prostascint demonstrated a sensitivity of 49-77% and specificity of 35-71%(14) . Despite this modestly improved performance compared with traditional imaging, Prostascint's relatively poor sensitivity in the setting of low PSAs, difficulties in anatomic localization owing to the limitations of SPECT, and significant operator dependence resulted in relatively limited use.
In an effort to improve upon these limitations, huJ591, a humanized monoclonal IgG1 antibody which binds an extracellular epitope of PSMA, has been developed for use with both gamma and photon-emitting metalloradionuclide agents (15) . The antibody has been employed in a number of early-phase clinical trials for both imaging and therapeutic purposes (16) (17) (18) (19) (Supplemental Table 1 ). Because IgG antibodies are not filtered at the glomerulus and remain within the blood pool for several days, imaging must be performed 6-8 days following infusion in order to allow clearance of the antibody from the blood pool. An 80-kDa minibody that has been genetically engineered to lack the Fc-receptor domain, known as 89 Zr-Df-IAB2M, was synthesized with the aim of generating faster blood clearance in to order to allow for imaging at a shorter time interval (20) . The initial studies suggest that a 48-hour wait time between infusion and imaging may still be required.
Small-molecule PSMA Ligands
Characterization of the active substrate-recognition site of the PSMA molecule has allowed for the development of numerous agents engineered to bind to this site. Small molecules have the theoretical advantage over antibodies of achieving better tumor penetration and more by NYU Med Ctr Lib -Periodicals Dept on October 6, 2017. For personal use only. jnm.snmjournals.org Downloaded from rapid clearance from the blood pool, allowing for infusion and imaging to be performed during a single patient-visit. Numerous small-molecule agents, labeled with a range of radionuclides for use with both SPECT and PET imaging, as well as for the delivery of radiometallonuclides for treatment purposes, have been developed and are in various stages of clinical use and development (Table 1, Supplemental Table 1 ). Several of the more promising small molecule agents are discussed below.
68
Ga-PSMA-HBED-CC ( 68 Ga-PSMA-11) is the most widely utilized PET agent for PSMA-targeted imaging. First described in 2012, the agent consists of the HBED-CC chelator to which the Gallium is bound, a lipophilic linker, and a urea-based Glu-CO-NH-Lys motif which binds to the active site of the PSMA molecule(21). It displays low-level natural uptake in the kidneys, salivary and lacrimal glands, liver, spleen and bowel, and has demonstrated the ability to detect prostate cancer within the prostate gland, within small nodal metastases, bony lesions, and even within more widespread de-differentiated tumors (22) (23) (24) . Because the agent is filtered at the glomerulus, high levels of activity are present in the urine, potentially making the detection of local recurrences more difficult; however nodal metastases near the bladder have been detected (24) . A systematic review was published in 2016 by Perera et al. evaluating the sensitivity and specificity of 68 G-PSMA-HBED-CC in various clinical settings (25) . Further details of the agent's performance will be discussed below.
Another area of robust investigation in PSMA ligands involves agents which utilize Fludeoxyglucose-18, a radionuclide which has several theoretical advantages over Gallium-68, including better image resolution owing to shorter positron range and higher positron yield. Like the Gallium agents, 18 F agents can be infused and imaged at the same visit. The first of these agents to be tested clinically was 18 F-DCFBC, which has been evaluated for use in disease by NYU Med Ctr Lib -Periodicals Dept on October 6, 2017. For personal use only. jnm.snmjournals.org Downloaded from assessment both within the gland(26) as well as for the detection of metastases (27, 28) . While initial results were encouraging, the significant blood pool activity of the agent prompted efforts to refine the agent and improve its performance. The result of these efforts was a secondgeneration agent, 18 F-DCFPyL, which was initially evaluated in a cohort of 9 patients with metastatic disease (29, 30) . As hoped, the agent demonstrated a marked improvement in maximum tumor-uptake-to-blood-pool-uptake ratios, (30) 
Biochemical Recurrence
At present, biochemical recurrence can be detected long before imaging technology allows anatomic localization of disease. This provides challenges for management because local radiotherapy, which is known to prolong both disease-free and overall survival (36) , is most effective when applied at low PSA levels, when, at present, local recurrence can only be inferred from pathologic data and PSA kinetics. Given reticence to proceed with local salvage radiotherapy without definitive evidence of a local recurrence, imaging technology to improve the localization of disease recurrence is of paramount interest, and represents one of the most robust areas of PSMA-targeted imaging research. Afshar-Oromieh et al. published the largest study for this indication, an analysis of 1007 men with biochemically recurrent disease(22) who underwent PET using the 68 G-PSMA-HBED-CC tracer. In 79.5% of patients, at least 1 lesion suggestive of prostate cancer was identified, including lesions in bone, soft tissue, and viscera.
There was a clear relationship between the likelihood of positive scan and PSA level: 46% (≤0.5ng/mL), 73% (0.51-1.0ng/mL), 80% (1.1-≤2.0ng/mL), 86% (2.1-≤3.0ng/mL), 91% (3.1-≤5.0ng/mL), 94% (5.1-≤7.0 ng/mL), 91% (7.1-≤10ng/mL), 96% (>10ng/mL). A multivariable logistic regression analysis found that log PSA and receipt of androgen deprivation therapy (37) with the incremental benefit of the PSMA study most pronounced in the subset of patients with a PSA <1 ng/mL.
Metastatic
The majority of published studies demonstrate that PSMA-targeting agents, both antibody-based and small molecule ligands, are safe and provide high sensitivity and specificity for staging lymph node, soft tissue, and bony metastases (20, 27, 29, 30, (38) (39) (40) (41) . One study by As such the true performance of PSMA-targeted imaging for metastatic disease remains incompletely evaluated at this time. Despite this, the initial studies provide strong preliminary evidence that PSMA-targeted imaging agents are likely to outperform traditional imaging procedures for the detection of metastatic disease. It is important to note that the value of molecular imaging to monitor therapy is, at present, unproven with respect to overall survival.
Unfortunately, molecular imaging is not included in ongoing large trials in advanced disease.
THERAPEUTIC TARGETING
Targeted cancer therapy aims to achieve sensitive and specific on-target, on-tumor cell death while sparing normal tissues. Great effort has been made to develop agents which target PSMA for treatment in the mCRPC disease state, with the appreciation that prostate cancer is radiosensitive prompting investigation into the use of radiopharmaceuticals as potential candidate effector agents. Most published studies of nascent radiopharmaceuticals are small molecule agents which utilized Lutetium-177 as the radiometal, but early-phase studies have evaluated antibody-based therapies as well. A summary of the key published reports is provided in Table 1 . Several notable agents are discussed below. No randomized studies exist to date.
The first PSMA-targeted radioimmunotherapeutic studies utilized the huJ591 antibody.
Two phase 1 dose-finding studies, one using 90 Y and one using 177 Lu, were published(18,19), followed by a phase 2 study using Table 2 ). The largest study to date is a retrospective multicenter cohort of 145 patients from 12 centers across Germany (47) . Some variation in efficacy outcomes is seen across the studies: following a single treatment, 59-79% of patients experienced a PSA decrease, with 32-45% of patients experiencing 50% decrease in PSA. In the studies by Rahbar et al. (47) and Kratochwil et al.(43) , there is the suggestion that patients who receive multiple treatments continued to respond to subsequent treatments at a similar, if not increasing, rate. The large German multicenter study demonstrated that the presence of visceral metastases and alkaline phosphatase ≥220 U/L predicted a lower rate of treatment response. In the study by Ahmadzadehfar et al., they observed that responders to the initial cycle of treatment survived over twice as long as non-responders (45) . In all cohorts leukopenia and thrombocytopenia were reported, but were mild. Xerostomia was seen but was mild and transient and rarely required salivary replacement. 
CONCLUSION
PSMA is a promising molecular target in prostate cancer management for a number of reasons, including high levels of expression on the majority of prostate cancer cells with limited expression on benign tissues, proven in vivo safety and feasibility of targeting PSMA using antibodies and small molecules, and an internalization motif which provides for internalization and concentration of agents. Performance characteristics of PET-based imaging assays have been shown in several studies to outperform standard imaging techniques, and appear poised to become a new standard in prostate cancer imaging. Early-phase therapeutic trials of unsealed radiometals have produced promising results in mCRPC, however more study will be required to prove their effect on meaningful endpoints. PSMA-targeting is likely to play a central role in prostate cancer management in the future.
